Article thumbnail
Location of Repository

Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells

By Kenyon G Daniel, Di Chen, Shirley Orlu, Qiuzhi Cindy Cui, Fred R Miller and Q Ping Dou
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2003). A: Cell death in human acute myelogenous leukemic cells induced by pyrrolidinedithiocarbamate. Apoptosis
  2. (1997). Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA
  3. (1996). AG: Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis.
  4. (1999). Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control
  5. (2001). Angiogenesis and melanoma. Curr Oncol Rep
  6. (2000). Angiogenesis: new targets for the development of anticancer chemotherapies. Curr Pharm Des
  7. (2001). Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol
  8. (1989). Balibrea JL: Serum and tissue trace metal levels in lung cancer. Oncology
  9. (1980). Cell death: the significance of apoptosis. Int Rev Cytol
  10. (2000). Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol.
  11. (1994). Chowdhery : Diagnostic and prognostic significance of serum and tissue trace elements in breast malignancy.
  12. (2004). Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg Chem
  13. (2002). Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia
  14. (2002). Concentrations of Fe, Cu and Zn in breast tissue: a synchrotron XRF study. Phys Med Biol
  15. (2002). Copper and carcinogenesis. Crit Rev Oncol Hematol
  16. (1983). Copper and zinc levels in normal and malignant tissues. Cancer
  17. (2001). Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood)
  18. (2002). Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res
  19. (2002). Copper uptake is required for pyrrolidine dithiocarbamate-mediated oxidation and protein level increase of p53 in cells.
  20. (2002). Development of the proteasome inhibitor PS-341. Oncologist
  21. (1992). Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.
  22. (1996). Dou QP: Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate. Cancer Res
  23. (1994). Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature
  24. (1998). Fairweather-Tait S: Adaptation to high and low copper intakes: its relevance to estimated safe and adequate daily dietary intakes.
  25. (2004). Farmer PJ: Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells.
  26. (2001). FR: Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat
  27. (1997). GM: p53-dependent induction of apoptosis by proteasome inhibitors.
  28. (2001). Gottfries CG: Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord
  29. (1995). H: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun
  30. (2003). Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases? Neuron
  31. (1997). JY: Degradation of retinoblastoma protein in tumor necrosis factor- and CD95-induced cell death.
  32. (1998). Lazebnik Y: Caspases: enemies within. Science
  33. (1996). Mazumder A: The effect of hydroxychloroquine on alloreactivity and its potential use for graftversus-host disease. Bone Marrow Transplant
  34. (1988). Mechanism of the neurotoxic and hepatotoxic effects of carbon disulfide. Drug Metabol Drug Interact
  35. (1995). Mechanisms and genes of cellular suicide.
  36. (2002). Merajver SD: Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia
  37. (1995). Nuclear changes in apoptosis.
  38. (2000). Pharmacological proteasome inhibitors and their therapeutic potential. Exp Opin Ther Patents
  39. (1999). PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res
  40. (1971). Prophylactic value of clioquinol against travellers' diarrhoea. Lancet
  41. (1999). Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat
  42. (2004). QP: Copper storage diseases: Menkes, Wilsons, and cancer. Front Biosci
  43. (1998). QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ
  44. (2004). QP: Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol
  45. (2005). RW: Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. J Vasc Surg
  46. (1996). S: Apoptosis induction resulting from proteasome inhibition.
  47. (2000). SB: Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev
  48. (2005). SE: Anticancer activity of the antibiotic clioquinol. Cancer Res
  49. (2002). Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res
  50. (1984). Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr
  51. (1977). Serum copper and ceruloplasmin levels in patients with neoplasias localized in the stomach, large intestine or lung. Tumori
  52. (1994). Serum trace elements and Cu/Zn ratio in malignant lymphomas in children.
  53. (1993). Serum ultrafiltrable copper, total copper and caeruloplasmin concentrations in gynaecological carcinomas. Ann Clin Biochem
  54. (2000). Sondak VK, et al.: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res
  55. (1980). SR: The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clin Chim Acta
  56. (2000). Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology
  57. (2003). Tammer A, et al.: Metalprotein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol
  58. (1999). TH: Association between oxidative stress and changes of trace elements in patients with breast cancer. Clin Biochem
  59. (1999). The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem
  60. (1994). The ubiquitin-proteasome proteolytic pathway. Cell
  61. (1999). Thiele DJ: Pipes and wiring: the regulation of copper uptake and distribution in yeast. Trends Microbiol
  62. (2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits betaamyloid accumulation in Alzheimer's disease transgenic mice. Neuron
  63. (1995). Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol
  64. (2003). Udupa SL: Copper and ceruloplasmin status in serum of prostate and colon cancer patients.
  65. (1997). VP: Serum levels of copper, zinc, iron and ceruplasmin in oral leukoplakia and squamous cell carcinoma.
  66. (1995). W: Proteasome from Thermoplasma acidophilum: a threonine protease. Science
  67. (2000). Wilding G: Angiogenesis inhibitors. New agents in cancer therapy. Drugs Aging

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.